Maxime Jullien

Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients

Patrice Chevallier, Marianne Coste‐Burel, Amandine Le Bourgeois et al. · eJHaem · 2021 · 38 citations · Full text

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study

Maxime Jullien, Sabrina Trudel, Benoît Tessoulin et al. · Annals of Hematology · 2019 · 33 citations

Hematological Malignancy, Single-agent Daratumumab, Medicine +4

SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine

Béatrice Clemenceau, Thierry Guillaume, Marianne Coste‐Burel et al. · Vaccines · 2022 · 28 citations · Full text

Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response

Dhon Roméo Makanga, Maxime Jullien, Gaëlle David et al. · OncoImmunology · 2021 · 18 citations · Full text

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study

Sabrina Trudel, Benoît Tessoulin, Maxime Jullien et al. · Annals of Hematology · 2019 · 15 citations

Hematological Malignancy, Oncology, Hematology +7